|
1
|
Liu H, Scholz C, Zang C, Schefe JH, Habbel
P, Regierer AC, Schulz CO, Possinger K and Eucker J: Metformin and
the mTOR inhibitor everolimus (RAD001) sensitize breast cancer
cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Anticancer Res. 32:1627–1637. 2012.PubMed/NCBI
|
|
2
|
Cheng K and Hao M: Metformin inhibits
TGF-β1-induced epithelial-to-mesenchymal transition via PKM2
relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells.
Int J Mol Sci. 17:E20002016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gwak H, Kim Y, An H, Dhanasekaran DN and
Song YS: Metformin induces degradation of cyclin D1 via
AMPK/GSK3beta axis in ovarian cancer. Mol Carcinog. 56:349–358.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gajjar K, Ogden G, Mujahid MI and Razvi K:
Symptoms and risk factors of ovarian cancer: A survey in primary
care. ISRN Obstet Gynecol. 2012:7541972012.PubMed/NCBI
|
|
5
|
Kasznicki J, Sliwinska A and Drzewoski J:
Metformin in cancer prevention and therapy. Ann Transl Med.
2:572014.PubMed/NCBI
|
|
6
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Okubo K, Isono M, Asano T and Sato A:
Metformin augments panobinostat's anti-bladder cancer activity by
activating AMP-activated protein kinase. Transl Oncol. 12:669–682.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moon HS, Kim B, Gwak H, Suh DH and Song
YS: Autophagy and protein kinase RNA-like endoplasmic reticulum
kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α)
pathway protect ovarian cancer cells from metformin-induced
apoptosis. Mol Carcinog. 55:346–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Binju M, Padilla MA, Singomat T, Kaur P,
Suryo Rahmanto Y, Cohen PA and Yu Y: Mechanisms underlying acquired
platinum resistance in high grade serous ovarian cancer - a mini
review. Biochim Biophys Acta Gen Subj. 1863:371–378. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Freimund AE, Beach JA, Christie EL and
Bowtell DDL: Mechanisms of drug resistance in high-grade serous
ovarian cancer. Hematol Oncol Clin North Am. 32:983–996. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rattan R, Giri S, Hartmann LC and Shridhar
V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase
dispensable manner. J Cell Mol Med. 15:166–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yasmeen A, Beauchamp MC, Piura E, Segal E,
Pollak M and Gotlieb WH: Induction of apoptosis by metformin in
epithelial ovarian cancer: Involvement of the Bcl-2 family
proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J,
Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic
activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li B, Li X, Ni Z, Zhang Y, Zeng Y, Yan X,
Huang Y, He J, Lyu X, Wu Y, et al: Dichloroacetate and metformin
synergistically suppress the growth of ovarian cancer cells.
Oncotarget. 7:59458–59470. 2016.PubMed/NCBI
|
|
16
|
Wheaton WW, Weinberg SE, Hamanaka RB,
Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM,
Budigner GS and Chandel NS: Metformin inhibits mitochondrial
complex I of cancer cells to reduce tumorigenesis. Elife.
3:e022422014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ter Braak B, Siezen CL, Lee JS, Rao P,
Voorhoeve C, Ruppin E, van der Laan JW and van de Water B:
Insulin-like growth factor 1 receptor activation promotes mammary
gland tumor development by increasing glycolysis and promoting
biomass production. Breast Cancer Res. 19:142017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kheirandish M, Mahboobi H, Yazdanparast M,
Kamal W and Kamal MA: Anti-cancer effects of metformin: Recent
evidences for its role in prevention and treatment of cancer. Curr
Drug Metab. 19:793–797. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sosnicki S, Kapral M and Weglarz L:
Molecular targets of metformin antitumor action. Pharmacol Rep.
68:918–925. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coccetti P, Nicastro R and Tripodi F:
Conventional and emerging roles of the energy sensor Snf1/AMPK in
saccharomyces cerevisiae. Microb Cell. 5:482–494. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikhlas S and Ahmad M: Metformin: Insights
into its anticancer potential with special reference to AMPK
dependent and independent pathways. Life Sci. 185:53–62. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Faubert B, Vincent EE, Poffenberger MC and
Jones RG: The AMP-activated protein kinase (AMPK) and cancer: Many
faces of a metabolic regulator. Cancer Lett. 356:165–170. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cerezo M, Tichet M, Abbe P, Ohanna M,
Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P,
Bertolotto C, et al: Metformin blocks melanoma invasion and
metastasis development in AMPK/p53-dependent manner. Mol Cancer
Ther. 12:1605–1615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mizushima N and Klionsky DJ: Protein
turnover via autophagy: Implications for metabolism. Ann Rev Nutr.
27:19–40. 2007. View Article : Google Scholar
|
|
27
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Galluzzi L, Pietrocola F, Bravo-San Pedro
JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J,
Gewirtz DA, Karantza V, et al: Autophagy in malignant
transformation and cancer progression. EMBO J. 34:856–880. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mathew R, Kongara S, Beaudoin B, Karp CM,
Bray K, Degenhardt K, Chen G, Jin S and White E: Autophagy
suppresses tumor progression by limiting chromosomal instability.
Genes Dev. 21:1367–1381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valente G, Morani F, Nicotra G, Fusco N,
Peracchio C, Titone R, Alabiso O, Arisio R, Katsaros D, Benedetto C
and Isidoro C: Expression and clinical significance of the
autophagy proteins BECLIN 1 and LC3 in ovarian cancer. Biomed Res
Int. 2014:4626582014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giatromanolaki AN, Charitoudis GS,
Bechrakis NE, Kozobolis VP, Koukourakis MI, Foerster MH and
Sivridis EL: Autophagy patterns and prognosis in uveal melanomas.
Mod Pathol. 24:1036–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Chao Y, Fang Y, Wang J, Wang M,
Zhang H, Ying M, Zhu X and Wang H: MTA1 promotes the invasion and
migration of non-small cell lung cancer cells by downregulating
miR-125b. J Exp Clin Cancer Res. 32:332013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marzook H, Li DQ, Nair VS, Mudvari P,
Reddy SD, Pakala SB, Santhoshkumar TR, Pillai MR and Kumar R:
Metastasis-associated protein 1 drives tumor cell migration and
invasion through transcriptional repression of RING finger protein
144A. J Biol Chem. 287:5615–5626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang H, Fan L, Wei J, Weng Y, Zhou L, Shi
Y, Zhou W, Ma D and Wang C: Akt mediates metastasis-associated gene
1 (MTA1) regulating the expression of E-cadherin and promoting the
invasiveness of prostate cancer cells. PloS One. 7:e468882012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mei ML, Li QL, Chu CH, Yiu CK and Lo EC:
The inhibitory effects of silver diamine fluoride at different
concentrations on matrix metalloproteinases. Dent Mater.
28:903–908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kumar R, Wang RA and Bagheri-Yarmand R:
Emerging roles of MTA family members in human cancers. Semin Oncol
30 (5 Suppl 16). 30–37. 2003.
|
|
37
|
Malisetty VL, Penugurti V, Panta P, Chitta
SK and Manavathi B: MTA1 expression in human cancers-clinical and
pharmacological significance. Biomed Pharmacother. 95:956–964.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F,
Yan Y, Shi J and Hu Y: microRNA-30c negatively regulates
endometrial cancer cells by targeting metastasis-associated gene-1.
Oncol Rep. 27:807–812. 2012.PubMed/NCBI
|
|
39
|
Bui-Nguyen TM, Pakala SB, Sirigiri RD, Xia
W, Hung MC, Sarin SK, Kumar V, Slagle BL and Kumar R: NF-kappaB
signaling mediates the induction of MTA1 by hepatitis B virus
transactivator protein HBx. Oncogene. 29:1179–1189. 2010.
View Article : Google Scholar : PubMed/NCBI
|
